Mesoblast (NASDAQ:MESO) Share Price Passes Below 50-Day Moving Average – Time to Sell?

Shares of Mesoblast Limited (NASDAQ:MESO) passed below its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $18.19 and traded as low as $15.55. Mesoblast shares last traded at $15.95, with a volume of 283,979 shares traded.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Mesoblast in a research report on Thursday, January 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy”.

Mesoblast Price Performance

The firm’s 50-day moving average is $18.19 and its 200-day moving average is $16.74. The company has a market capitalization of $2.06 billion, a PE ratio of -18.13 and a beta of 2.15. The company has a quick ratio of 1.77, a current ratio of 1.99 and a debt-to-equity ratio of 0.11.

Institutional Trading of Mesoblast

Several hedge funds and other institutional investors have recently bought and sold shares of the company. NBC Securities Inc. bought a new position in Mesoblast during the fourth quarter valued at approximately $89,000. Mirae Asset Global Investments Co. Ltd. raised its position in Mesoblast by 30.6% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,383 shares of the company’s stock worth $43,000 after purchasing an additional 558 shares during the period. BCS Private Wealth Management Inc. purchased a new position in Mesoblast in the 4th quarter worth $289,000. Choreo LLC lifted its stake in Mesoblast by 15.1% in the fourth quarter. Choreo LLC now owns 12,225 shares of the company’s stock worth $227,000 after purchasing an additional 1,600 shares during the last quarter. Finally, Rialto Wealth Management LLC purchased a new stake in Mesoblast during the fourth quarter valued at about $839,000. Hedge funds and other institutional investors own 1.43% of the company’s stock.

Mesoblast Company Profile

Mesoblast Limited is a global leader in allogeneic cellular medicines, focused on developing treatments for inflammatory and immunologic diseases. Founded in 2004 by Dr. Silviu Itescu, the company builds on proprietary mesenchymal lineage cell technology to create off-the-shelf, donor-derived therapies. These therapies are designed to modulate immune responses and promote tissue repair in conditions where existing medical options are limited or ineffective.

The company’s most advanced product, Alofisel® (darvadstrocel), has been approved in Europe for the treatment of complex perianal fistulas in adults with Crohn’s disease.